SCHEMBL3756320

SCHEMBL3756320

CCOC(=O)Cc1nc(NC(=O)c2cc(S(=O)(=O)c3cccs3)cn2Cc2ccc(Cl)c(F)c2)sc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
NPSR1 Q6W5P4 1/20 0.34
KMT2A Q03164 4/20 0.34
TSHR P16473 3/20 0.34
GAA P10253 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PTGER3 P43115 2/20 0.33
GCK P35557 2/20 0.33
PKM P14618 1/20 0.33
ALDH1A1 P00352 3/20 0.32
MEN1 O00255 2/20 0.32
POLB P06746 2/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
P2RX7 Q99572 2/20 0.32
GRM4 Q14833 2/20 0.32
SENP7 Q9BQF6 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661013 0.95 GRM4 (0.36) NPC1RAB9ANPSR1KMT2ATSHR
SCHEMBL2660829 0.90 GCK (0.38) KMT2APTGER3GCKMEN1GRM4
SCHEMBL3756302 0.85 GCK (0.39) NPC1RAB9AKMT2APTGER3GCK
SCHEMBL2660774 0.82 GCK (0.34) NPC1RAB9AKMT2ATSHRGAA
SCHEMBL15104129 0.81 SCN3A (0.38) NPC1RAB9AKMT2APTGER3MEN1
SCHEMBL15104179 0.81 SCN3A (0.36) NPC1RAB9ANPSR1KMT2ATSHR
SCHEMBL13504170 0.80 SCN3A (0.36) NPSR1KMT2ATSHRHSD17B10PTGER3
SCHEMBL3748494 0.78 PDE3B (0.37) NPSR1KMT2AGAAPTGER3GCK
SCHEMBL2662504 0.76 GCK (0.35) NPC1RAB9AKMT2ATSHRGAA
SCHEMBL27796914 0.76 GCK (0.36) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP claimed
US-8299115-B2 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2012-10-30 US claimed
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-11-18 US claimed
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP disclosed
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION GCK, PCK1, GCKR NPC1 3612/4885RAB9A 3498/4885NPSR1 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.